HLS Therapeutics Q1 2023 Investor Presentation

HLS Therapeutics is a Canadian-based, North American-focused pharmaceutical company with $61.5M in 2022 revenue and $23.8M adjusted EBITDA. The company operates 7 products across cardiovascular and central nervous system therapeutic areas, with 4 in commercial stage and others in pre-launch or regulatory review. This Q1 2023 presentation outlines the company's growth strategy and operational performance.